{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonate&page=7", "query": { "condition": "Neonate", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 11257, "total_pages": 1126, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonate&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonate&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T10:43:22.746Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02230761", "title": "Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lower Eyelid Steatoblepharon (Excess Eyelid Fat)" ], "interventions": [ { "name": "XOPH5 Ointment", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Topokine Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2014-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02230761" }, { "nct_id": "NCT00004483", "title": "NF2 Natural History Consortium", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Schwannoma, Vestibular", "Neurofibromatosis 2", "Meningioma" ], "interventions": [], "intervention_types": [], "sponsor": "House Ear Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 100, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-09-29", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004483" }, { "nct_id": "NCT07159841", "title": "A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Congenital Adrenal Hyperplasia", "Classic Congenital Adrenal Hyperplasia" ], "interventions": [ { "name": "Atumelnant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Crinetics Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 153, "start_date": "2026-01-22", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-11-05", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07159841" }, { "nct_id": "NCT02373241", "title": "Preventing Sickle Cell Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia, Sickle Cell", "Sickle Cell Disease", "Kidney Disease", "Hypertension", "Proteinuria" ], "interventions": [ { "name": "Losartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "5 Years to 25 Years" }, "enrollment_count": 1, "start_date": "2015-04", "completion_date": "2021-07", "has_results": true, "last_update_posted_date": "2024-04-03", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02373241" }, { "nct_id": "NCT07869654", "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Friedreich Ataxia", "Cardiomyopathies", "Central Nervous System Diseases", "Neuromuscular Diseases", "Mitochondrial Diseases", "Mitochondrial Dysfunction", "Genetic Disease" ], "interventions": [ { "name": "ATI-105", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adjuvia Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 60, "start_date": "2026-10-26", "completion_date": "2027-06-27", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07869654" }, { "nct_id": "NCT03907072", "title": "Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "WVE-210201 (suvodirsen)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wave Life Sciences USA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "12 Years", "sex": "MALE", "summary": "5 Years to 12 Years · Male only" }, "enrollment_count": 6, "start_date": "2019-09-04", "completion_date": "2020-01-09", "has_results": true, "last_update_posted_date": "2021-05-20", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03907072" }, { "nct_id": "NCT02750501", "title": "Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "RELiZORB (immobilized lipase) cartridge", "type": "DEVICE" }, { "name": "Impact Peptide 1.5", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Alcresta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 49, "start_date": "2016-07-20", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-08-15", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 10, "location_summary": "Hollywood, Florida • Boise, Idaho • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Portland", "state": "Maine" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02750501" }, { "nct_id": "NCT00411619", "title": "Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tuberous Sclerosis", "Subependymal Giant Cell Astrocytoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 28, "start_date": "2007-01", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00411619" }, { "nct_id": "NCT04468919", "title": "Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Amyotrophic Lateral Sclerosis", "Brainstem Stroke", "Muscular Dystrophies", "Parkinson's Disease and Parkinsonism", "Multiple System Atrophy", "Brain Tumor Adult", "Spinal Cord Injuries", "Locked-in Syndrome" ], "interventions": [ { "name": "BCI-FIT multi-modal access", "type": "BEHAVIORAL" }, { "name": "BCI-FIT adaptive signal modeling", "type": "BEHAVIORAL" }, { "name": "BCI-FIT active querying", "type": "BEHAVIORAL" }, { "name": "BCI-FIT language modeling", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 55, "start_date": "2022-07-15", "completion_date": "2025-05-05", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04468919" }, { "nct_id": "NCT01872819", "title": "Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Chronic Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Refractory Anemia With Excess Blasts" ], "interventions": [ { "name": "antitumor drug screening assay", "type": "OTHER" }, { "name": "chemotherapy", "type": "DRUG" }, { "name": "biological therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2013-08-02", "completion_date": "2014-11-17", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-11-07T10:43:22.746Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01872819" } ] }